BioSpace News Archive

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted LYPDISO™ as the proposed brand name for MAT9001, the Company’s investigational drug for treatment of cardiovascular and metabolic conditio

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will participate in the upcoming 39th Annual J.P. Morgan Healthcare Conference.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board of directors. Mr. Marek succeeds Lynn Seely, M.D.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will present a corporate overview at the 39 th Annual J.P. Morgan Healthcare Conference. The conference will be held in a vi

Objectives of CARES10 ( C linical A ssessment of pha R macokinetics, E fficacy, S afety of a 10 % Ig), a phase III, open-label, prospective, multi-center study were to assess the efficacy

Bristol Myers Squibb to Present at J.P. Morgan’s 39 th Annual Virtual Healthcare Conference

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team will participate at two upcoming virtual investor events.

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, will host a virtual R&D Day on Thursday, January 7, 2021 from 09:00 am to 10:30 am ET to discuss Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia (FA).

Paragonix Technologies , the leading hypothermic cardiothoracic organ preservation provider, announced today that Bill Edelman, Chief Executive Officer and Chairman of the Board, will present at in the 23 rd Annual Needham Virtual Growth Conference on January 11-15 th , 2021 in a series of virtual 1:1 meetings reviewing the company’s rapid int

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven”) today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive disorder (OCD).